Trials / Terminated
TerminatedNCT00179699
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 | |
| DRUG | pemetrexed |
Timeline
- Start date
- 2005-09-01
- Completion
- 2006-11-01
- First posted
- 2005-09-16
- Last updated
- 2005-11-07
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00179699. Inclusion in this directory is not an endorsement.